交银医药创新股票C(014046)利润分配表
|
2025-06-30 |
2024-12-31 |
2024-06-30 |
2023-12-31 |
收入 |
378,620,448.96 |
-478,146,401.85 |
-564,838,220.62 |
-349,095,869.64 |
利息合计 |
683,162.25 |
1,655,139.02 |
843,113.54 |
1,790,476.81 |
其中:存款利息收入 |
612,331.93 |
1,655,139.02 |
843,113.54 |
1,790,476.81 |
债券利息收入 |
- |
- |
- |
- |
资产支持证券利息收入 |
- |
- |
- |
- |
买入返售金融资产收入 |
70,830.32 |
- |
- |
- |
投资收益合计 |
56,030,738.74 |
-644,848,564.08 |
-347,448,392.64 |
-146,098,732.42 |
其中:股票投资收益 |
40,247,900.45 |
-696,983,133.97 |
-384,450,803.18 |
-182,327,765.03 |
基金投资收益 |
- |
- |
- |
- |
债券投资收益 |
- |
1,063,169.39 |
450,599.96 |
323.44 |
资产支持证券投资收益 |
- |
- |
- |
- |
衍生工具收益 |
- |
- |
- |
- |
股利收益 |
15,782,838.29 |
51,071,400.50 |
36,551,810.58 |
36,228,709.17 |
基金分红收益收益 |
- |
- |
- |
- |
公允价值变动收益 |
321,570,094.97 |
162,823,397.65 |
-219,544,341.04 |
-206,561,671.99 |
其他收入 |
336,453.00 |
2,223,625.56 |
1,311,399.52 |
1,774,057.96 |
费用 |
16,094,143.99 |
42,614,049.24 |
24,036,554.56 |
63,315,828.12 |
管理人报酬 |
13,447,619.70 |
35,095,471.90 |
19,602,416.32 |
52,351,882.71 |
基金托管费 |
2,241,269.98 |
5,849,245.26 |
3,267,069.33 |
8,725,313.76 |
销售服务费 |
310,866.54 |
1,469,441.36 |
1,062,528.10 |
2,028,163.94 |
交易费用 |
- |
- |
- |
- |
利息支出 |
- |
- |
- |
- |
其中:卖出回购金融资产支出 |
- |
- |
- |
- |
其他费用 |
94,132.79 |
199,887.82 |
104,539.42 |
210,467.71 |
利润总额 |
362,526,304.97 |
-520,760,451.09 |
-588,874,775.18 |
-412,411,697.76 |
欢迎访问证券之星!请点此与我们联系 版权所有: Copyright © 1996-年